A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children
← catalyst calendarNCT06305663 · readout in 165 d
Sponsored by Bausch & Lomb Incorporated (industry) · BLCO — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
418estimated
Sites
11
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-29 | actual | When the study began enrolling |
| Primary completion | 2027-01-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myopia
Interventions
- Device: Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)
- Device: CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens
Primary outcomes
what the primary-completion date above is the date OFMean change from baseline in axial length.
measured 1 and 2 years
Mean change from baseline in cycloplegic SERE.
measured 1 and 2 years
Permalink · BLCO's whole pipeline · Catalyst calendar · Every registered study · What changed